Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
Ambrosia Biosciences has raised $100.0M in total funding. The most recent round was Series B. The last funding was announced in March 2026.
Ambrosia Biosciences's investors include Janus Henderson Investors, Samsara BioCapital, Blue Owl, Redmile Group, Merck.
Ambrosia Biosciences is headquartered in Boulder, United States.
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
Ambrosia Biosciences is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ambrosia Biosciences — Funding & Investors." VCBacked, March 31, 2026, https://www.vcbacked.co/company/ambrosia-biosciences. Accessed August 15, 2026.
VCBacked. (2026). Ambrosia Biosciences — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/ambrosia-biosciences
{{cite web |title=Ambrosia Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/ambrosia-biosciences |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated